PH-762 is under clinical development by Phio Pharmaceuticals and currently in Phase I for Merkel Cell Carcinoma. According to GlobalData, Phase I drugs for Merkel Cell Carcinoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PH-762’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PH-762 overview

PH-762 is under development for the treatment of solid tumors, melanoma, ovarian cancer, colon cancer, head and neck squamous cell cancer, Merkel Cell Carcinoma, hepatocellular carcinoma, metastatic melanoma, triple-negative breast cancer and cutaneous Squamous Cell Carcinoma. It comprises tumor infiltrating lymphocytes modified with sd-rxRNAi (self-deliverable RNAi). It is administered through intratumorally and through subcutaneous route The drug candidate acts by targeting programmed cell death protein 1(PD1). It is developed based INTASYL therapeutic platform.

Phio Pharmaceuticals overview

Phio Pharmaceuticals, formerly known as RXi Pharmaceuticals, is a biotechnology company. The company discovers, develops and commercializes immuno-oncology therapeutics-based RNAi platform to treat cancer. Its product pipeline includes PH-762, PH-894 and PH-804 for adoptive cell therapy, tumor microenvironment and intratumoral. Phio Pharmaceuticals also provides clinical trial services. Phio Pharmaceuticals offers products for the treatment of anti scarring, macular degeneration, retinoblastoma and liver diseases. The company partners with academia, biotech and large multi-national organizations for the development of new therapeutics. Phio Pharmaceuticals is headquartered in Marlborough, Massachusetts, the US.

For a complete picture of PH-762’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.